Celsion Corporation (NASDAQ:CLSN) declined to $0.26 per share in the last trading day compared to a prior close of $0.28. The management team hold 1 percent of the stock. Egwu, Inc. FkaEgen, Inc. ranks as top insider in Celsion Corporation, noted in the Company’s filings with the U.S. Securities and Exchange Commission. The insider’s stake of 2,421,867 shares is worth $629,685. Tardugno Michael H is ranked No.2 with 143,021 shares as of Oct 07, 2016, which sits at a market value around $37,185. Martinez Alberto R Jr is another big name in this category. This insider owns 80,081 CLSN shares, amounting to about $20,821 as of recent trading price which is -19.87% below its 20-day moving average and -71.55% below its 50-day moving average. The equity dropped -59.47% over the trailing 3 months.

Celsion Corporation (NASDAQ:CLSN) on March 9, 2017 announced that the Company will host a conference call to discuss year-end 2016 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. ET on Thursday, March 16, 2017. Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) shares closed at $1.77, up 0.07 points or 4.41 percent from  the previous close price. The up to date insider trading filings show President and CEO SOUTHWELL DAVID P has picked up 60,000 shares,upping the ownership to 62,765 units. The transaction occurred on Jan 06, 2017, at $1.75 per share worth a total $105,000. There was another major transaction on the insider-trading front. CARROLL J MARTIN, Director at ITEK bought 10,000 common shares at a per share price of $9.03 to hold 10,000 shares. The stock recently traded at a volume of 0 shares vs. an average volume of 1.11M. The latest closing price is now lower -74.46% for the past quarter. The price is now -7.24% below its 50-day moving average and -71.37% below its 200-day moving average. The percentage change return over the last fifty two weeks remained -74.16%. The price range in the same period had a highest hit of $10.9 while lowest level in that period was $1.5.

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the United States. The company’s lead product candidate includes Trabodenoson, a monotherapy that is in Phase III clinical trials for lowering IOP by restoring the eye’s natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a fixed-dose combination prostaglandin analogue, which has completed the Phase II clinical trials for IOP-lowering in patients who have previously had inadequate response to latanoprost, as well as Trabodenoson monotherapy that is in pre-clinical studies for the treatment of optic neuropathy and degenerative retinal diseases.